EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma

Maxwell L Weng iD, Tereza Vitkovska, Song Hon Hwang iD, Lauran K Evans, Hong-Ho Yang, Christopher Dann, Dipti Sajed, Maie A St John iD

The Laryngoscope · 2026

DOI: 10.1002/lary.70584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Maxwell L Weng und 7 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Immunocompromised Host, Oropharyngeal Neoplasms, Papillomavirus Infections, Human Papillomavirus Viruses. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To characterize the survival and morbidity associated with immunocompromised status in patients with surgically resected Human Papillomavirus positive oropharyngeal squamous cell carcinoma (HPV + OPSCC).

Methods

We reviewed patients with surgically resected HPV + OPSCC at a tertiary institution between 2000 and 2023. The survival and morbidity associated with an immunocompromised status were assessed with multivariable Cox proportional hazards models controlling for patient, tumor, and treatment characteristics.

Results

Among 278 patients with HPV+ OPSCC that met inclusion criteria, 14 patients were immunocompromised. Causes of immunocompromise: 4, leukemia or lymphoma; 3, organ transplantation; 3, medically immunosuppressed; 2, HIV; 2, myelodysplastic syndrome and pancytopenia. Adjusting for covariates, the immunocompromised patient group had significantly worse overall survival (64.3% vs. 91.7%; HR 4.12, 95% CI: 1.14–14.90, p < 0.005) compared to the non‐compromised group. The immunocompromised patient group did not have a significantly different postoperative length of stay (3.96 vs. 3.5 days; aβ 0.66, 95% CI: −1.30 to 2.64).

Conclusions

In this small, heterogeneous cohort of surgically resected HPV + OPSCC, immunocompromised status was associated with significantly worse overall survival; however, these exploratory findings should be interpreted cautiously. Level of Evidence 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostOropharyngeal NeoplasmsPapillomavirus InfectionsHuman Papillomavirus VirusesCarcinoma, Squamous CellHumansFemaleMaleMiddle AgedRetrospective StudiesAgedComorbidity

Stichwörter der Autor:innen

HIVHPV‐associated oropharyngeal squamous cell carcinomaimmunocompromiseleukemialymphomaorgan transplantationpancytopeniatransoral robotic surgery (TORS)

Autor:innen und Institutionen

  • David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Department of Head & Neck Surgery, David Geffen School of Medicine, Los Angeles, California, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA.
  • Department of Pathology, David Geffen School of Medicine, Los Angeles, California, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Maxwell L Weng, Song Hon Hwang, Maie A St John

Zitieren

APA

Weng, M. L., Vitkovska, T., Hwang, S. H., Evans, L. K., Yang, H. H., Dann, C., Sajed, D., & St John, M. A. (2026). Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma. The Laryngoscope. https://doi.org/10.1002/lary.70584

Vancouver

Weng ML, Vitkovska T, Hwang SH, Evans LK, Yang HH, Dann C, et al. Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma. The Laryngoscope. 2026. doi:10.1002/lary.70584

BibTeX
@article{Weng2026,
  author = {Weng, Maxwell L and Vitkovska, Tereza and Hwang, Song Hon and Evans, Lauran K and Yang, Hong-Ho and Dann, Christopher and Sajed, Dipti and St John, Maie A},
  title = {Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.70584}
}
Kostenlos starten →